An evaluation of palbociclib as a breast cancer treatment option: a current update

References

• Palbociclib (Ibrance) package insert [Internet]; [ cited 2020 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212436lbl.pdf
   Google Scholar
• Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812–821.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Roussel MF, Ashmun RA, et al. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell. 1991;65:701–713.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993;7:331–342.
   PubMed Web of Science ®Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753–761.
   PubMed Web of Science ®Google Scholar
• Cobrinik D, Whyte P, Peeper DS, et al. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 1993;7:2392–2404.
   PubMed Web of Science ®Google Scholar
• Zhu L, van den Heuvel S, Helin K, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 1993;7:1111–1125.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6:353–367.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Luo RX, Dei Santi A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98:859–869.
   PubMed Web of Science ®Google Scholar
• Yao G, Lee TJ, Mori S, et al. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008;10:476–482.
   PubMed Web of Science ®Google Scholar
• Massagué J. G1 cell-cycle control and cancer. Nature. 2004;432:298–306.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77–83.
   PubMed Web of Science ®Google Scholar
• Paternot S, Bockstaele L, Bisteau X, et al. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle. 2010;9:689–699.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Sotillo R, Santamaría D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118:493–504.
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9:23–32.
   PubMed Web of Science ®Google Scholar
• Liu -M-M, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277:24353–24360.
   PubMed Web of Science ®Google Scholar
• Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17:5338–5347.
   PubMed Web of Science ®Google Scholar
• Zwijsen RML, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–415.
   PubMed Web of Science ®Google Scholar
• Gillett C, Fantl V, Smith R. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994;54(7):1812–1817.
   Google Scholar
• Kenny FS, Hui R, Musgrove EA, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:2069–2076.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res BCR. 2009;11:R77.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Raspé E, Coulonval K, Pita JM, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med. 2017;9:1052–1066.
   PubMed Web of Science ®Google Scholar
• Álvarez-Fernández M, Malumbres M. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell. 2020;37:514–529.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:568–576.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104:1862–1868.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Loibl S, Turner NC, Ro J, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017;22:1028–1038.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–1936.
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017–1021.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22:438–451.
   PubMed Web of Science ®Google Scholar
• Nikolai BC, Lanz RB, York B, et al. HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes. Cancer Res. 2016;76:1463–1475.
   PubMed Web of Science ®Google Scholar
• Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29:255–269.
   PubMed Web of Science ®Google Scholar
• Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19:249–256.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:5505–5512.
   PubMed Web of Science ®Google Scholar
• Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29–33.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Gong X, Litchfield LM, Webster Y, et al. Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell. 2017;32:761–776.e6.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:995–1001.
   PubMed Web of Science ®Google Scholar
• Clark AS, McAndrew NP, Troxel A, et al. Combination paclitaxel and palbociclib: results of a phase i trial in advanced breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:2072–2079.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767.
   PubMed Web of Science ®Google Scholar
• Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 Inhibition in triple-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:5561–5572.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Edelweiss M, Patil S, et al. Abstract P3-11-04: phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). Poster Sess Abstr [Internet]. American Association for Cancer Research; 2018 [cited 2020 Jun 4]. p. P3-11-04-P3-11–04. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-P3-11–04
   Google Scholar
• Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–1949.
   PubMed Web of Science ®Google Scholar
• Cottu P, D’Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:2334–2340.
   PubMed Web of Science ®Google Scholar
• Johnston S, Puhalla S, Wheatley D, et al. Randomized phase ii study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:178–189.
   PubMed Web of Science ®Google Scholar
• Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:4055–4065.
   PubMed Web of Science ®Google Scholar
• Bagegni N, Thomas S, Liu N, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017;19:123.
   PubMed Web of Science ®Google Scholar
• Arnedos M, Bayar MA, Cheaib B, et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1755–1762.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Lond Engl. 2011;378:771–784.
   PubMedGoogle Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–1846.
   PubMed Web of Science ®Google Scholar
• Pfizer provides update on phase 3 PALLAS trial of Ibrance® (palbociclib) plus endocrine therapy in HR+, HER2- early breast cancer [Internet]; 2020 [cited 2020 Jun 10]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-pallas-trial-ibrancer
   Google Scholar
• Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20:1750–1759.
   PubMed Web of Science ®Google Scholar
• Martín M, Zielinski C, Ruíz-Borrego M, et al. Abstract GS2-07: results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Gen Sess Abstr [Internet]. American Association for Cancer Research; 2020 [cited 2020 Sep 23]. p. GS2-07-GS2-07. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS19-GS2–07
   Google Scholar
• Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20:1360–1369.
   PubMed Web of Science ®Google Scholar
• Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20:1587–1601.
   PubMed Web of Science ®Google Scholar
• Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: tREnd trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1748–1754.
   PubMed Web of Science ®Google Scholar
• Schettini F, De Santo I, Rea C, et al. Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series. Mol Clin Oncol [Internet]. 2020 [cited 2020 Sep 23]; Available from. ; http://www.spandidos-publications.com/10.3892/mco.2020.2016
   PubMed Web of Science ®Google Scholar
• Rastogi P, Toi M, Harbeck N, et al. Abstract OT3-05-05: monarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer. Ongoing Clin Trials [Internet]. American Association for Cancer Research; 2018 [cited 2020 Jul 20]. p. OT3-05-05-OT3-05–05. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-OT3-05–05
   Google Scholar
• Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer [Internet]; 2020 [cited 2020 Jun 30]. Available from: https://investor.lilly.com/news-releases/news-release-details/verzenior-abemaciclib-significantly-reduced-risk-cancer
   Google Scholar
• Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20:620–634.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–475.
   PubMed Web of Science ®Google Scholar
• Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immunomodulation. Biochem Pharmacol. 2019;170:113676.
   PubMed Web of Science ®Google Scholar
• Ameratunga M, Kipps E, Okines AFC, et al. To cycle or fight—CDK4/6 inhibitors at the crossroads of anticancer immunity. Clin Cancer Res. 2019;25:21–28.
   PubMed Web of Science ®Google Scholar